Trial reportAmerican heart journal2008
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).
Trial report in American heart journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00133692 (INternational VErapamil SR Trandolapril STudy), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
INternational VErapamil SR Trandolapril STudy
Who cites it
21 citing papers in PubMed, 50 citations in OpenAlex.
- Single nucleotide polymorphism rs4961 in the adducin 1 gene is not associated with gastric cancer or preneoplastic cancer lesions.Oncology letters · 2024Article
- The adducin saga: pleiotropic genomic targets for precision medicine in human hypertension-vascular, renal, and cognitive diseases.Physiological genomics · 2022Review
- Race and genetics versus 'race' in genetics: A systematic review of the use of African ancestry in genetic studies.Evolution, medicine, and public health · 2021Review
- A Mutation inJournal of the American Society of Nephrology : JASN · 2020Article
- Gut microbiota and serum metabolite differences in African Americans and White Americans with high blood pressure.International journal of cardiology · 2018Article
- Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.Expert review of precision medicine and drug development · 2018Article
- Personalized Management of Cardiovascular Disorders.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2017Review
- Hypertension pharmacogenomics: in search of personalized treatment approaches.Nature reviews. Nephrology · 2016Review
- Characteristics associated with informed consent for genetic studies in the ACCORD trial.Contemporary clinical trials · 2014Article
- Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.Pharmacogenomics · 2012Review
- Cardiovascular pharmacogenomics.Circulation research · 2011Review
- Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.Pharmacogenetics and genomics · 2011Article
- Gene-drug interaction in stroke.Stroke research and treatment · 2011Article
- Expectations, validity, and reality in pharmacogenetics.Journal of clinical epidemiology · 2010Review
- The Pharmacogenomics of Anti-Hypertensive Therapy.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Pharmacogenomics of antihypertensive drugs: past, present and future.Pharmacogenomics · 2010Article
- Genetic association studies and the effect of misclassification and selection bias in putative confounders.BMC proceedings · 2009Article
- Pharmacogenetics and stroke.Stroke · 2009Review
- INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.Expert review of cardiovascular therapy · 2009Article
- CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.Circulation. Cardiovascular genetics · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe alpha-adducin (ADD1) Gly460Trp polymorphism has been associated with hypertension and response to diuretic therapy, but controversy exists.
methodsThe present study was conducted to prospectively investigate the relationship among the ADD1 Gly460Trp polymorphism, diuretic use, and adverse cardiovascular outcomes among 5,979 patients with hypertensive coronary artery disease, who participated in the INVEST and provided genomic DNA. The primary outcome was defined as the first occurrence of nonfatal stroke, nonfatal myocardial infarction, or all-cause death. Secondary outcomes were the components of the primary outcome. Ancestry informative markers were used to control for population stratification.
resultsIn blacks, ADD1 variant carriers were at higher risk for a primary outcome event than wild-type homozygotes (adjusted hazard ratio 2.62, 95% CI 1.23-5.58, P = .012), with a similar trend in whites and Hispanics, albeit a smaller magnitude of effect (adjusted hazard ratio 1.43, 0.86-2.39 in Hispanics; 1.24, 0.90-1.71 in whites). Secondary outcome analysis showed that the all-cause death was driving the differences in primary outcomes by genotype. There was no interaction between the ADD1 polymorphism and diuretic use for either primary outcome or secondary outcomes.
conclusionsIn hypertensive patients with coronary artery disease, black ADD1 variant carriers showed a 2.6-fold excess risk for a primary outcome event and an 8-fold increase risk of death. White and Hispanic ADD1 variant carriers showed an increased but nonsignificant excess risk. However, the effect of diuretic use on risk of cardiovascular outcomes did not vary by ADD1 carrier status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.